Clinical assessment of subdermal implants of megestrol acetate, d-norgestrel, and norethindrone as a longterm contraceptive in women

Croxatto, Horacio B.; Dı́az, Soledad; Quinteros, Eliana; Simoneti, Luis Fernando; Kaplan, Elina; Rencoret, R; Leixelard, P.; Martínez, Consuelo Prado

doi:10.1016/s0010-7824(75)80045-x

Cited by 32 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data on the effect of progestin dose on ectopic pregnancy risk are limited; however, a couple of studies provide some evidence. In a study in which women received 90-or 120-mg LNG implants, an ectopic pregnancy incidence rate of 8.3 per 1000 women-years was observed for the two groups combined [62], which is considerably higher than even the highest rates observed in studies of Norplant or Jadelle, which contain 216 and 150 mg of LNG, respectively. This may be because lower dose implants have a lower daily release rate and thus are less effective in preventing pregnancy, including ectopic pregnancy.…”

Section: Dose Effectmentioning

confidence: 79%

Ectopic pregnancy with use of progestin-only injectables and contraceptive implants: a systematic review

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Dose Effectmentioning

confidence: 79%

Ectopic pregnancy with use of progestin-only injectables and contraceptive implants: a systematic review

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Of the 17 studies reporting pregnancy and continuation outcomes, ten used life-table analysis, 44,[64][65][66]72,74,76,77,79,82 one used PIs 83 and the remaining six used other methods. In only two studies was it possible to determine whether single or multiple decrement life tables had been used.…”

Section: Non-randomised Prospective Cohort Studiesmentioning

confidence: 99%

“…Ten of the 19 studies provided a description of contraceptive methods before enrolment. 44,62,64,66,74,[77][78][79]82,83 In the ten studies reporting pregnancy outcomes, 44,62,64,66,74,[77][78][79]82,83 six provided sufficient information to distinguish between user and method failure. 44,64,66,74,79,83 None of the studies conducted active follow-up analysis.…”

Section: Non-randomised Prospective Cohort Studiesmentioning

confidence: 99%

“…Data from 18 of the 34 studies that met the inclusion criteria were included in the metaanalysis. Five studies were excluded from the metaanalysis because they were investigations of prototypes 45,50,57,61,83 and it was deemed inappropriate to pool their data. We were unable to determine the types of IUDs used as the controls in one study 63 and it was not possible to extract any data from the remaining studies, 66,68,77 as neither single decrement life-table probabilities with SEs nor events over time were reported.…”

Section: Quantitative Synthesis Of Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Implantable contraceptives (subdermal implants and hormonally impregnated intrauterine systems) versus other forms of reversible contraceptives: two systematic reviews to assess relative effectiveness, acceptability, tolerability and cost-effectiveness.

French

Cowan²,

Mansour³

et al. 2000

Health Technology Assessment

109

View full text Add to dashboard Cite

et al. Implantable contraceptives (subdermal implants and hormonally impregnated intrauterine systems) versus other forms of reversible contraceptives: two systematic reviews to assess relative effectiveness, acceptability, tolerability and cost-effectiveness. Health Technol Assess 2000;4(7). Health Technology Assessment is indexed in Index Medicus/MEDLINE and Excerpta Medica/ EMBASE. Copies of the Executive Summaries are available from the NCCHTA website (see overleaf). NHS R&D HTA Programme T he overall aim of the NHS R&D Health Technology Assessment (HTA) programme is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and work in the NHS. Research is undertaken in those areas where the evidence will lead to the greatest benefits to patients, either through improved patient outcomes or the most efficient use of NHS resources. The Standing Group on Health Technology advises on national priorities for health technology assessment. Six advisory panels assist the Standing Group in identifying and prioritising projects. These priorities are then considered by the HTA Commissioning Board supported by the National Coordinating Centre for HTA (NCCHTA). This report is one of a series covering acute care, diagnostics and imaging, methodology, pharmaceuticals, population screening, and primary and community care. It was identified as a priority by the Pharmaceutical Panel and funded as project number 95/41/01. The views expressed in this publication are those of the authors and not necessarily those of the Standing Group, the Commissioning Board, the Panel members or the Department of Health. The editors wish to emphasise that funding and publication of this research by the NHS should not be taken as implicit support for the recommendations for policy contained herein. In particular, policy options in the area of screening will be considered by the National Screening Committee. This Committee, chaired by the Chief Medical Officer, will take into account the views expressed here, further available evidence and other relevant considerations. Reviews in Health Technology Assessment are termed 'systematic' when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. Criteria for inclusion in the HTA monograph series Reports are published in the HTA monograph series if (1) they have resulted from work either prioritised by the Standing Group on Health Technology, or otherwise commissioned for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

show abstract

“…In many clinical trials different steroids were examined as candidates for long-acting implant contraception. Among possible agents considered, megestrol acetate, levonorgestrel and nor-gestrienone were chosen for further testing because of their few side effects, long duration of action and high efficacy (18,19).…”

Section: Development Of Norplantr Implantsmentioning

confidence: 99%

Contraception With Subdermal Implants Releasing Levonorgestrel

Olsson

1987

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

Clinical assessment of subdermal implants of megestrol acetate, d-norgestrel, and norethindrone as a longterm contraceptive in women

Cited by 32 publications

References 9 publications

Ectopic pregnancy with use of progestin-only injectables and contraceptive implants: a systematic review

Ectopic pregnancy with use of progestin-only injectables and contraceptive implants: a systematic review

Implantable contraceptives (subdermal implants and hormonally impregnated intrauterine systems) versus other forms of reversible contraceptives: two systematic reviews to assess relative effectiveness, acceptability, tolerability and cost-effectiveness.

Contraception With Subdermal Implants Releasing Levonorgestrel

Contact Info

Product

Resources

About